News Column

Findings on Immunoglobulins Detailed by A. Mukherjee and Co-Authors (Development and Screening of a Series of Antibody-Conjugated and Silica-Coated...

August 22, 2014



Findings on Immunoglobulins Detailed by A. Mukherjee and Co-Authors (Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen)

By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Immunology have been presented. According to news originating from San Diego, California, by NewsRx correspondents, research stated, "The prostate-specific membrane antigen (PSMA) is an established target for the delivery of cancer therapeutic and imaging agents due to its high expression on the surface of prostate cancer cells and within the neovasculature of other solid tumors. Here, we describe the synthesis and screening of antibody-conjugated silica-coated iron oxide nanoparticles for PSMA-specific cell targeting."

Our news journalists obtained a quote from the research, "The humanized anti-PSMA antibody, HuJ591, was conjugated to a series of nanoparticles with varying densities of polyethylene glycol and primary amine groups. Customized assays utilizing iron spectral absorbance and enzyme-linked immunoassay (ELISA) were developed to screen microgram quantities of nanoparticle formulations for immunoreactivity and cell targeting ability. Antibody and PSMA-specific targeting of the optimized nanoparticle was evaluated using an isogenic PSMA-positive and PSMA-negative cell line pair. Specific nanoparticle targeting was confirmed by iron quantification with inductively coupled plasma mass spectrometry (ICP-MS)."

According to the news editors, the research concluded: "These methods and nanoparticles support the promise of targeted theranostic agents for future treatment of prostate and other cancers."

For more information on this research see: Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen. Chemmedchem, 2014;9(7):1356-1360. Chemmedchem can be contacted at: Wiley-V C H Verlag Gmbh, Boschstrasse 12, D-69469 Weinheim, Germany. (Wiley-Blackwell - www.wiley.com/; Chemmedchem - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1860-7187)

The news correspondents report that additional information may be obtained from A. Mukherjee, NanoComposix Inc, San Diego, CA 92111, United States. Additional authors for this research include T. Darlington, R. Baldwin, C. Holz, S. Olson, P. Kulkarni, T.L. DeWeese, R.H. Getzenberg, R. Ivkov and S.E. Lupold (see also Immunology).

Keywords for this news article include: Antibodies, San Diego, California, Immunology, Nanoparticle, United States, Blood Proteins, Nanotechnology, Immunoglobulins, Emerging Technologies, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters